Preventive Prescribing of Laxatives for Opioid-induced Constipation Using Electronic Clinical Rule Implementation by Cinical Pharmacists

A. J. Scheepers-Hoeks, R. Grouls, C. Neef, Anne-Marie J Doppen, Erik H M Korsten
{"title":"Preventive Prescribing of Laxatives for Opioid-induced Constipation Using Electronic Clinical Rule Implementation by Cinical Pharmacists","authors":"A. J. Scheepers-Hoeks, R. Grouls, C. Neef, Anne-Marie J Doppen, Erik H M Korsten","doi":"10.4172/2167-1052.1000159","DOIUrl":null,"url":null,"abstract":"Objective: The objective of this study was: (1) to develop and validate an electronic clinical rule for ‘Opioid-Laxative Use’ and to implement this rule in clinical pharmacy practice; (2) to improve guideline compliance by using this refined clinical rule; and (3) to investigate if opioid-induced constipation (OIC) can be reduced in hospitalised patients by the application of this clinical rule. \nMethods: Interventions using clinical rule alerts were performed between June and September 2009. We \ncompared guideline compliance before and after the intervention to determine the difference. Interventions consisted of telephone consultations by a clinical pharmacist advising physicians to add a laxative to opioid therapy. Patient files were matched to a historical control group using an opioid without a laxative to examine the difference between intervention- and control patients in the presence of OIC. \nResults: Prospective validation of the rule resulted in several refinements. In the intervention period, 140 alerts were generated, 60 of which (43%) led to co-prescription of a laxative. Therefore, guideline compliance increased from 70% to 83%. A significant difference in OIC was found between the intervention group (12%) and the control group (56%). \nConclusions: This study showed that pharmacy intervention based on an electronic clinical rule for ´Opioid-Laxative Use´ led to more adequate co-prescription of opioids and laxatives. This led to a better compliance with the guideline as well as a better outcome, as measured by the significant decrease in the prevalence of OIC.","PeriodicalId":7385,"journal":{"name":"Advances in Pharmacoepidemiology and Drug Safety","volume":"11 1","pages":"1-5"},"PeriodicalIF":0.0000,"publicationDate":"2014-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacoepidemiology and Drug Safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2167-1052.1000159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

Objective: The objective of this study was: (1) to develop and validate an electronic clinical rule for ‘Opioid-Laxative Use’ and to implement this rule in clinical pharmacy practice; (2) to improve guideline compliance by using this refined clinical rule; and (3) to investigate if opioid-induced constipation (OIC) can be reduced in hospitalised patients by the application of this clinical rule. Methods: Interventions using clinical rule alerts were performed between June and September 2009. We compared guideline compliance before and after the intervention to determine the difference. Interventions consisted of telephone consultations by a clinical pharmacist advising physicians to add a laxative to opioid therapy. Patient files were matched to a historical control group using an opioid without a laxative to examine the difference between intervention- and control patients in the presence of OIC. Results: Prospective validation of the rule resulted in several refinements. In the intervention period, 140 alerts were generated, 60 of which (43%) led to co-prescription of a laxative. Therefore, guideline compliance increased from 70% to 83%. A significant difference in OIC was found between the intervention group (12%) and the control group (56%). Conclusions: This study showed that pharmacy intervention based on an electronic clinical rule for ´Opioid-Laxative Use´ led to more adequate co-prescription of opioids and laxatives. This led to a better compliance with the guideline as well as a better outcome, as measured by the significant decrease in the prevalence of OIC.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
临床药师应用电子临床规则预防处方阿片类药物引起的便秘
目的:本研究的目的是:(1)制定和验证“阿片类泻药使用”的电子临床规则,并在临床药学实践中实施该规则;(2)通过使用该改进的临床规则提高指南的依从性;(3)研究阿片类药物引起的便秘(OIC)是否可以通过应用这一临床规则来减少住院患者。方法:2009年6 - 9月采用临床规则提示进行干预。我们比较干预前后的指南依从性来确定差异。干预措施包括由临床药师电话咨询,建议医生在阿片类药物治疗中添加泻药。患者档案与使用阿片类药物而不使用泻药的历史对照组相匹配,以检查存在OIC的干预组和对照组患者之间的差异。结果:该规则的前瞻性验证导致了一些改进。在干预期间,产生了140个警报,其中60个(43%)导致共同处方泻药。因此,指南依从性从70%增加到83%。OIC在干预组(12%)和对照组(56%)之间有显著差异。结论:本研究表明,基于“阿片类泻药使用电子临床规则”的药学干预导致阿片类药物和泻药的联合处方更充分。通过OIC患病率的显著下降,这使得指南得到了更好的遵守,结果也更好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Antidepressant: An Overview Quantification of 3?-Acetyl-11-Keto-?-Boswellic Acid and 11-Keto-?Boswellic Acid in the Resin of Boswellia species by HPTLC The Use of 3D Models to Test Potential Anti-SARS-CoV-2 Drugs and Infection Mechanisms Local Drug Delivery in Periodontal Therapy: A Contemporary Review Challenges of Hepatotoxicity Associated with Isoniazid Preventive Therapy among People Living with HIV in Eritrea
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1